Pliant Therapeutics Inc
PLRX1.740USD
+0.160+10.13%
Horário de mercado （ET）Cotações atrasadas em 15 min
106.81MValor de mercado
PerdaP/L TTM
Mais detalhes de Pliant Therapeutics Inc Empresa
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.
Informações da empresa
Código da empresaPLRX
Nome da EmpresaPliant Therapeutics Inc
Data de listagemJun 03, 2020
CEODr. Bernard J. Coulie, M.D., Ph.D.
Número de funcionários171
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 03
Endereço331 Oyster Point Boulevard
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Telefone16504816770
Sitehttps://pliantrx.com/
Código da empresaPLRX
Data de listagemJun 03, 2020
CEODr. Bernard J. Coulie, M.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
705.63K
-8.97%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-68.53%
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Dr. Delphine Imbert, Ph.D.
Dr. Delphine Imbert, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
705.63K
-8.97%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-68.53%
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 2 de jul
Atualizado em: qua, 2 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Tang Capital Management, LLC
9.77%
Deep Track Capital LP
8.80%
BlackRock Institutional Trust Company, N.A.
7.40%
The Vanguard Group, Inc.
4.89%
Cormorant Asset Management, LP
4.89%
Other
64.25%
Investidores
Investidores
Proporção
Tang Capital Management, LLC
9.77%
Deep Track Capital LP
8.80%
BlackRock Institutional Trust Company, N.A.
7.40%
The Vanguard Group, Inc.
4.89%
Cormorant Asset Management, LP
4.89%
Other
64.25%
Tipos de investidores
Investidores
Proporção
Hedge Fund
35.59%
Investment Advisor
28.68%
Investment Advisor/Hedge Fund
19.92%
Research Firm
5.73%
Venture Capital
4.24%
Individual Investor
3.04%
Family Office
0.87%
Bank and Trust
0.30%
Pension Fund
0.22%
Other
1.42%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
370
63.27M
103.07%
-13.14M
2025Q1
390
63.45M
103.37%
-12.99M
2024Q4
392
71.13M
116.20%
-8.66M
2024Q3
388
69.61M
114.50%
-7.63M
2024Q2
375
69.93M
115.87%
-7.66M
2024Q1
371
73.36M
121.74%
-3.24M
2023Q4
362
70.03M
116.83%
-95.89K
2023Q3
356
64.13M
107.25%
-2.06M
2023Q2
347
62.06M
104.99%
-496.00K
2023Q1
337
60.53M
102.92%
+8.55M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Tang Capital Management, LLC
6.00M
9.77%
+6.00M
--
Mar 31, 2025
Deep Track Capital LP
5.40M
8.8%
-572.58K
-9.59%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.54M
7.4%
+52.45K
+1.17%
Mar 31, 2025
The Vanguard Group, Inc.
3.33M
5.42%
+105.82K
+3.29%
Mar 31, 2025
Cormorant Asset Management, LP
3.00M
4.89%
+3.00M
--
Mar 31, 2025
Blue Owl Capital Holdings LP
2.97M
4.84%
+200.00K
+7.22%
Mar 31, 2025
UBS Financial Services, Inc.
2.65M
4.31%
+2.02M
+321.08%
Mar 31, 2025
Woodline Partners LP
2.51M
4.1%
+2.39M
+1875.01%
Mar 31, 2025
Third Rock Ventures, LLC
2.13M
3.47%
--
--
Mar 31, 2025
Redmile Group, LLC
2.05M
3.35%
-841.92K
-29.08%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Vanguard US Value Factor ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
SPDR S&P Pharmaceuticals ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
Ver Mais
Vanguard US Value Factor ETF
Proporção0.02%
ProShares Ultra Nasdaq Biotechnology
Proporção0.01%
iShares Biotechnology ETF
Proporção0.01%
iShares Micro-Cap ETF
Proporção0.01%
Invesco Nasdaq Biotechnology ETF
Proporção0.01%
FlexShares Morningstar US Market Factor Tilt Index Fund
Proporção0%
DFA Dimensional US Core Equity Market ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
SPDR S&P Pharmaceuticals ETF
Proporção0%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
